<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261179</url>
  </required_header>
  <id_info>
    <org_study_id>2019-003825-56</org_study_id>
    <nct_id>NCT04261179</nct_id>
  </id_info>
  <brief_title>Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer</brief_title>
  <acronym>SENTINELSEEK</acronym>
  <official_title>An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Cruceta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of
      lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nodal Concordance: proportion of lymph nodes identified by 99mTc-tilmanocept vs nanocolloidal human serum albumin by lymphoscintigraphies</measure>
    <time_frame>for at least 48 consecutive hours</time_frame>
    <description>number and diameter in millimeters of nodes affected identified by 99mTc-tilmanocept vs nanocolloidal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time frame to ascertain the sentinel nodes</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance among early and delayed images obtained withLymphoseek® or with albumianocolloid and the SPECT/CT images.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sentinel nodes and secondary nodes depicted</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracer retention in injection site</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of 99mTctilmanocept (Lymphoseek®)</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Lymphoseek® or with albuminanocolloid</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head Cancer</condition>
  <condition>Neck Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Lymphoseek + Nanocoll</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lymphoseek</intervention_name>
    <description>50 μg microgram(s), timepoint: 30-60 minutes</description>
    <arm_group_label>Lymphoseek + Nanocoll</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanocoll</intervention_name>
    <description>500 μg microgram(s), timepoint: 30-60 minutes</description>
    <arm_group_label>Lymphoseek + Nanocoll</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically confirmed diagnosis of melanoma, breast cancer or head and neck cancer
             and candidate for surgical resection with lymph node mapping being a part of the
             surgical plan.

          -  At least 18 years of age at the time of consent.

          -  The subject is clinically node negative (cN0) at the time of screening.

          -  In Melanoma Patients

               -  Diagnosis of primary melanoma with sentinel node indication ( &gt;0.8 mm Breslow
                  thickness; clinically negative lymph nodes)

          -  In Breast Cancer Patients

               -  T1-T2 N0 breast cancer.

               -  Patients with pure ductal carcinoma in situ (DCIS) if lymph node biopsy is part
                  of the surgical plan.

          -  In Oral cavity tumors patients

               -  T1-T2 N0 oral cavity squamous cell carcinoma

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Clinical or radiological evidence of metastatic cancer including palpably abnormal or
             enlarged lymph nodes

          -  Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy

          -  Patients who have undergone node basin surgery of any type or radiation to the nodal
             basin(s) potentially draining the primary tumor

          -  Patients who have undergone a wide excision for their tumor or complex reconstruction
             (rotation, free flap or skin graft of any type).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínico y provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Cruceta Arboles, MD</last_name>
      <email>acruceta@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

